LSD1은 급성 골수성 백혈병, 소세포 폐암 및 기타 여러 암종을 포함한 다양한 암의 유망한 치료 표적으로 부상하고 있습니다. 이러한 악성 종양에서는 LSD1 수준의 상승이 지적되고 있으며, 암세포의 증식, 침윤, 이동, 분화에 기여하고 있습니다. 저분자 억제제를 이용한 LSD1의 약리학적 억제는 LSD1에 돌이킬 수 없거나 가역적으로 결합하는 억제제에서 효능을 나타냅니다. 돌이킬 수없는 LSD1 억제제는 일반적으로 TCP 구조를 가지며 FAD 보조 효소와 공유 결합하여 억제를 달성합니다. LSD1의 조절 이상과 과발현은 전립선암, 유방암, 방광암, 수아종, 신경아종, 신경교종, 육종, AML과 같은 혈액 악성 종양 등 다양한 암의 전이와 종양 형성에 관여하고 있습니다. 이 광범위한 참여는 암 병인에서 LSD1이 중요한 역할을 담당하고 있으며, 그 치료 표적으로서의 가능성을 강조하고 있습니다. LSD1을 의약품으로 억제하는 것은 암 치료 전략으로 유망합니다. 현재의 연구는 여러 TCP 기반 LSD1 억제제의 치료 가능성을 평가합니다. 또한, 천연물도 LSD1 억제제로서의 효능을 나타냅니다. 이러한 천연물은 고리형 펩티드, 프로토베르베린 알칼로이드, 폴리페놀, 불포화 카르보닐 화합물 등의 범주로 분류되어 LSD1을 표적으로 하는 잠재적 치료제의 레퍼토리를 확장하고 있습니다.
발암에서 LSD1의 중요한 관여와 LSD1이 다양한 신호전달 경로에 간섭하는 수많은 방법 때문에 라이신 탈메틸화효소, 특히 LSD1을 표적으로 하는 것은 암 환자에 대한 유망한 치료 옵션이 되고 있습니다.
Oryzon Genomics, Salarius Pharmaceuticals, Jubilant Therapeutics, Merck와 같은 주요 기업들은 다양한 적응증을 위한 LSD1 억제제 개발에 종사하고 있습니다.
본 보고서는 라이신 탈메틸화효소 1(LSD1)의 주요 7개 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에 대한 조사 분석을 통해 각 지역 시장 규모와 예측, 현재 치료법, 신약, 미충족 수요(Unmet Needs) 등의 정보를 제공합니다.
DelveInsight's "Lysine demethylase 1 (LSD1) - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the LSD1 Inhibitor, historical and competitive landscape as well as the LSD1 Inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The LSD1 inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM LSD1 inhibitors market size from 2020 to 2034. The report also covers current LSD1 inhibitors treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Study Period: 2020-2034
LSD1 inhibitors Understanding
LSD1 Inhibitors Overview
LSD1, also known as KDM1A, belongs to the monoamine oxidase (MAO) family and shares a sequence similarity with monoamine oxidases A and B (MAO-A, MAO-B), as well as a similarity with polyamine oxidase (PAO). LSD1 inhibitors can be grouped into covalent and non-covalent agents. Each group includes some hybrid compounds, able to inhibit LSD1 in addition to other target(s) at the same time (dual or multitargeting compounds). In tumor cells, the overexpression of LSD1 induces abnormal cell proliferation, thereby facilitating the rapid growth and extensive dissemination of tumors. Effectively inhibiting the expression or function of LSD1 can mitigate the proliferation and dissemination of tumor cells, thereby markedly enhancing the therapeutic efficacy against cancer. Consequently, LSD1 has emerged as a compelling target for the development of anti-tumor drugs.
LSD1 has been found significantly overexpressed in many solid tumors, including prostate, breast, small cell lung cancer, bladder cancer, medulloblastoma, neuroblastoma, glioma, and sarcomas, as well as hematological malignancies, such as acute myeloid leukemia.
The LSD1 inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total incident cases of selected indication for LSD1 inhibitors, total eligible patient pool for LSD1 inhibitors in selected indication, total treated cases in selected indication for LSD1 inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of the LSD1 inhibitors reports encloses a detailed analysis of LSD1 inhibitors late-stage, mid-stage, and early-stage pipeline drugs. It also helps understand the LSD1 inhibitors' clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
Seclidemstat (SP-2577): Salarius Pharmaceuticals
Seclidemstat is a novel oral reversible inhibitor of the LSD1 enzyme and has received fast-track, orphan drug, and rare pediatric disease designations for Ewing sarcoma from the FDA. In addition to the MDACC investigator-initiated clinical trial, seclidemstat has been studied in a company-sponsored Phase I/II clinical trial evaluating its use in combination with TC for the treatment of relapsed/refractory Ewing sarcoma.
Bomedemstat: Imago Biosciences/Merck (MSD)
Bomedemstat (MK-3543) is an investigational small molecule, irreversible LSD 1 inhibitor being developed by Merck. LSD 1 regulates the proliferation of hematopoietic stem cells, playing an essential role in cell differentiation and maturation. Bomedemstat is being evaluated in a wide range of MPNs, including essential thrombocythemia, myelofibrosis and polycythemia. Bomedemstat has US Food and Drug Administration Orphan Drug and Fast Track Designations for the treatment of ET and myelofibrosis (MF), Orphan Drug Designation for the treatment of acute myeloid leukemia and Priority Medicines scheme designation by the European Medicines Agency for the treatment of MF.
LSD1 has emerged as a promising therapeutic target for various cancers, including acute myeloid leukemia, small-cell lung cancer, and several other cancer types. Elevated levels of LSD1 have been noted in these malignancies, contributing to cancer cell proliferation, invasion, migration, and differentiation. Pharmacological inhibition of LSD1 using small molecule inhibitors has shown effectiveness, with inhibitors either irreversibly or reversibly binding to LSD1. Irreversible LSD1 inhibitors typically feature the TCP structure, interacting covalently with the FAD cofactor to achieve inhibition. LSD1's dysregulation or overexpression has been implicated in metastasis and tumorigenesis across a spectrum of cancers, including prostate, breast, bladder cancer, medulloblastoma, neuroblastoma, glioma, sarcomas, and hematological malignancies like AML. This broad involvement underscores LSD1's significant role in cancer pathogenesis and its potential as a therapeutic target. Pharmaceutical inhibition of LSD1 has shown promise as a treatment strategy for cancer. Current research is evaluating several TCP-based LSD1 inhibitors for their therapeutic potential. Additionally, natural products have also demonstrated effectiveness as LSD1 inhibitors. These natural products fall into categories such as cyclic peptides, protoberberine alkaloids, polyphenols, and unsaturated carbonyl compounds, expanding the repertoire of potential therapeutic agents targeting LSD1.
Due to the important involvements of LSD1 in carcinogenesis, and the numerous ways with which it interferes with various signaling pathways, targeting lysine demethylases and in particular LSD1 is becoming a promising treatment option for cancer patients.
Key players, including Oryzon Genomics, Salarius Pharmaceuticals, Jubilant Therapeutics, Merck, and others, are involved in developing drugs for LSD1 inhibitors for various indications.
This section focuses on the uptake rate of emerging LSD1 inhibitors expected to be launched in the market during 2025-2034.
LSD1 Inhibitors Pipeline Development Activities
The report provides insights into different therapeutic candidates in different Phases of development. It also analyzes key players involved in developing targeted therapeutics.
The presence of numerous drugs under different stages is expected to generate immense opportunity for LSD1 Inhibitors market growth over the forecast period.
Pipeline development activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for LSD1 inhibitors emerging therapies.
The increasing strategic collaborations among major market players to enhance the growth of their pipeline products are anticipated to drive market expansion.
KOL Views
To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the LSD1 Inhibitors evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.
DelveInsight's analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Texas MD Anderson Cancer Center, American Lung Association, Wings for Ewing Sarcoma, etc. were contacted.
Their opinion helps understand and validate LSD1 Inhibitor market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.
In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Key Updates on LSD1 Inhibitors